Trial · NCT07588698
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
NCT07588698, Phase 2, Not yet recruiting, Carrie Ho, MD
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma. Trials, record NCT07588698. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07588698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
- NCT number
- NCT07588698
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Carrie Ho, MD
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone, Positron Emission Tomography (PET), Blood specimen collection, Questionnaires, Computerized tomography (CT)
- First posted
- 2026-05-15
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cytokine Release Syndrome (CRS) Rate | Up to day 42 | The cytokine release syndrome (CRS) rate is defined as the incidence of CRS of any grade during Cycle 2, graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria. The proportion and corresponding 95% confidence interval will be reported. |
| Secondary | Proportion of Participants with Treatment-emergent Adverse Events | Up to 60 days after treatment | Proportion of participants with treatment-emergent adverse events, classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The proportion and 95% confidence interval will be reported. |
| Secondary | Overall Response (OR) | Up to 2 years | Overall response (OR) is defined as the proportion of treated participants who obtained an radiographic objective response confirmed complete response (CR) or confirmed partial response (PR) per Lugano Classification. The proportion and 95% confidence interval will be reported. |
| Secondary | Duration of Overall Response | Up to 2 years | Duration of overall response is defined as the time from first documentation of complete response (CR) or partial response (PR) to the first occurrence of disease progression, recurrence, or death, whichever occurs first. Patients without progression who are alive at the clinical cutoff will be censored at the date of their last disease assessment. Median, estimates and 95% confidence interval will be reported using the Kaplan-Meier method and Brookmeyer and Crowley method. |
| Secondary | Median Progression-Free Survival (PFS) | Up to 2 years | Progression-free survival (PFS) is the time from the first dose of treatment until disease progression or death, whichever occurs first. If neither event occurs, PFS is measured up to the last adequate disease assessment. If a patient is alive but has no tumor assessments after starting treatment, PFS is measured up to the first dose date. Median, estimates and 95% confidence interval will be reported using the Kaplan-Meier method and Brookmeyer and Crowley method. |
| Secondary | Median Overall Survival (OS) | Up to 2 years. | Overall survival (OS) is the time from the first dose of treatment until death from any cause. Patients who are still alive will be followed up to their last known contact date. Median, estimates and 95% confidence interval will be reported using the Kaplan-Meier method and Brookmeyer and Crowley method. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07588698
GET https://conductscience.org/api/trials/v1/NCT07588698/registered